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any advances have been made in the past
decade in the treatment of schizophrenia. There have
also been advances in the understanding the etiopatho-
physiology of schizophrenia, with much work studying
neurochemical, neuroanatomical, genetic, and post-
mortem domains. New research has focused on early
detection of schizophrenia, cognitive impairments, and
improving long-term outcomes for patients who suffer
from this devastating illness.
1-3 Progress has been par-
ticularly due to a new class of medications the second-
generation antipsychotics (SGAs), which have become
available in the last 7 years. However, despite these
research efforts,there is still a great deal that we do not
know about schizophrenia.Most studies and clinical tri-
als involve participation of adults (18–65 years) who do
not have substance-abuse problems and are free from
other concomitant disease states,medications,and other
symptom domains. Therefore, although it is a growing
area, clinical research and understanding of optimal
treatment for special patient populations has received
little recognition.
This paper will review the current state of treatment for
schizophrenic patients who are considered to be in spe-
cial patient populations;these include children and ado-
lescents,the elderly,substance abusers,and patients who
are considered to be resistant to traditional medications.
Treatment of schizophrenia 
in adolescents
Epidemiological data show that 10% to 30% of patients
with schizophrenia develop their first psychotic symp-
toms prior to their 18th birthday.
4-6 Onset before the age
of 18, but beyond puberty is sometimes classified as
early-onset schizophrenia or intermediate-onset schizo-
phrenia and those presenting with symptoms before the
ages of 12 to 14 years (prepubertal) are labeled as
patients with very-early-onset schizophrenia or as hav-
ing childhood-onset schizophrenia.
7 More male adoles-
cents (2:1) may develop very-early-onset schizophrenia
than females; however, the overall prevalence at this
young age is very low:1/10 000.
8
The diagnosis of schizophrenia in children and adoles-
cents is often difficult to make and should be differenti-
ated from pervasive developmental disorders,attention-
deficit/hyperactivity disorder, and language or
communication disorders. If a child has prominent hal-
lucinations or delusions,however,the diagnosis of schiz-
ophrenia should be considered.Auditory hallucinations
are common and occur in approximately 80% of chil-
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Special patient populations with schizophrenia have
received little attention. These populations include adoles-
cents, the elderly, substance abusers, and patients who are
considered treatment-resistant. Interest in these popula-
tions is rapidly growing, especially with regard to their treat-
ment with second-generation antipsychotics. This article
describes the treatment of special patient populations and
summarizes the research that has been done in this field.dren and adolescents with schizophrenia.Command hal-
lucinations are the most frequently occurring type of
hallucination. The content and context of delusions in
children and adolescents are varied by age with younger
children tending to be less complex and less “fixed.”
8-10
Some 54% to 90% of patients developing schizophrenia
before age 18 will have premorbid abnormalities such as
withdrawal,odd traits,and isolation.
11,12
Treatment for psychotic children and adolescents ide-
ally involves an intensive and comprehensive program.
A highly structured environment with special education
and psychoeducation is recommended. Day treatment,
hospitalization, or long-term residential treatment may
be necessary. Pharmacologic treatment is indicated if
positive psychotic symptoms cause significant impair-
ments or interfere with other interventions.Traditional
antipsychotics have modest efficacy in children and ado-
lescents at doses between 10 to 200 chlorpromazine
equivalents. Few studies with the conventional antipsy-
chotics have been published in this population. Three
controlled clinical trials to examine the safety and effi-
cacy in children and adolescents with schizophrenia have
been published.
13-16 The low-potency agents should be
particularly avoided in this population because of seda-
tion and anticholinergic side effects, which may lead to
cognitive dulling and interference with schoolwork.Chil-
dren and adolescents are also more vulnerable to
extrapyramidal side effects (EPS), namely dystonias,
than adults.
13,15,16 Due to concerns with EPS and tardive
dyskinesia (TD) in this group, many children and ado-
lescents are initiated on SGAs and traditional agents
are not generally used as first-line therapy.
Several open trials and case series have reported the
use of clozapine in children and adolescents for the
treatment of schizophrenia.
17-21 Kumra et al
22 compared
clozapine with haloperidol in a double-blind fashion in
patients aged 6 to 18 with a poor response to antipsy-
chotics.The dosage of clozapine ranged from 25 to 525
mg/day with a mean dosage of 176 mg/day. Clozapine
was found to be superior to haloperidol and particu-
larly beneficial for negative symptoms.Although most
young patients have improvement during clozapine
therapy, side effects in this population may be more
pronounced and frequent than in adults. The most
prominent symptoms seen are somnolence, hypersali-
vation,and weight gain.Children and adolescents tend
on average to gain more weight than reported in the
adult literature. Mean weight gains are up to 7 kg in 6
weeks.
17 Seizures have been reported and may be more
frequent than the 3% to 6% prevalence in adults.The
risk for agranulocytosis appears to be similar to adults.
Children and adolescents who have been found to be
resistant to at least two trials of antipsychotics including
another SGA may benefit from a trial of clozapine,but
it should be used only as a last resort therapy. Young
patients should be treated initially with lower doses
than adult patients and be titrated at a slower rate.Side
effects should be monitored closely during initiation
and throughout maintenance therapy. Enuresis may
occur with clozapine and often occurs at higher rates in
children and adolescents.
The number of published reports of the use of risperi-
done in children and adolescents has been growing
rapidly in the past couple of years. Several reports of
risperidone use for patients with pervasive developmen-
tal disorders have been published.
23-26Additionally,many
recent publications cite risperidone use for conduct dis-
order, aggression, bipolar disorder, developmental dis-
abilities, and obsessive compulsive disorder.
27-34 Studies
and reports for the treatment of schizophrenia, how-
ever,are rare.Armenteros et al
35 published a short-term,
open-label study for 10 adolescents with a diagnosis of
schizophrenia.Although responses similar to the adult
population were seen, the mean dosage used was very
high, 6.6 mg/day (range 4–10 mg/day), and well beyond
what is currently used clinically for adolescents and
adults alike. All other reports for patients with schizo-
phrenia, to our knowledge, have been case reports and
chart reviews.Dosing of risperidone in current reports in
diseases other than schizophrenia generally use initial
dosages of 0.25 to 0.5 mg/day and stabilize patients on
dosages of 1.5 to 3 mg/day. Risperidone is known to
cause EPS in adults as dosing increases above 6 mg/day.
36
Because young patients are more susceptible to these
effects and optimal efficacy is known to occur at lower
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Selected abbreviations and acronyms
AD Alzheimer’s disease
BPRS Brief Psychiatric Rating Scale
EPS extrapyramidal side effect
PANSS Positive and Negative Syndrome Scale
PD Parkinson’s disease
SGA second-generation antipsychotic
TD tardive dyskinesiadoses,
37 the dosage of risperidone for the treatment of
schizophrenia in children and adolescents should be in
the range of 0.5 to 4 mg/day.
Children and adolescents more often report tiredness
and sedation with risperidone treatment than adults.
32
Also unlike the adult population,there have been a few
reports of stereotypies and elevations in liver enzymes
occurring.
24,38 Other side effects, apart from weight gain,
are usually mild and similar to the adult population.
Weight gain has been fairly well documented in the ado-
lescent population and appears more pronounced than in
adults. Kelly et al
39 reported mean gains of 8.7 kg over 6
months of treatment with risperidone—significantly
more than that of traditional antipsychotics (3.0 kg) or no
antipsychotic (-1.0 kg) during the same period. Martin
and colleagues
40 reported clinically significant weight
gains in 78% of children and adolescents treated with
risperidone compared with 24% in a comparison group;
the average weight gain was 1.2 kg/month.Risperidone is
known to cause the greatest prolactin elevations of the
SGAs dependent on both dose and dopamine D2 recep-
tor occupancy.
41At higher doses,there have been reports
of menstrual irregularities occurring in young patients
42
and galactorrhea has occurred in both sexes during clin-
ical treatment.When side effects occur,lowering the dose
of risperidone has often been found to be effective.
Olanzapine,like risperidone,has been widely studied in
adult populations,
43 but data for adolescents with schiz-
ophrenia are scarce. The only study in the adolescent
schizophrenic population
44 reported an open trial of
olanzapine in patients aged 10 to 17 years. The mean
dosage was 17.5 mg/day and the side effects reported
included weight gain, increased appetite, anticholiner-
gic side effects, and sedation. Difficulty concentrating,
sustained tachycardia, headache, nausea and vomiting,
and transient liver elevations were also reported in this
study. Although not comparatively studied, olanzapine
treatment in young populations appears to cause greater
weight gains than risperidone:Potenza
45 reported over 8
kg in only 12 weeks of treatment. Unlike the transient
rise and fall in the adult population, a recent report
found sustained prolactin elevation in 70% of children
and adolescents treated with olanzapine, but little has
been published regarding clinical side effects of this phe-
nomenon.
46The mean dosages being used in the adoles-
cent population are between 5 and 20 mg/day. It is not
yet clear what is the ideal dose range for olanzapine in
this group.
There is one open-label trial of quetiapine in adoles-
cents with psychotic disorders reporting an improve-
ment from baseline in both positive and negative symp-
toms. The most commonly occurring side effects were
postural tachycardia and insomnia.
47 Currently, little is
known about the most appropriate dosing for this pop-
ulation. Dosages of 200 to 800 mg/day are being
reported.More research is needed to ascertain the safety
and dosing of quetiapine,especially in the young popu-
lation.
SGAs show great promise in the treatment of psychotic
symptoms in patients who are under the age of 18 for
symptom improvement and tolerability. Dosing for
clozapine and risperidone in particular should be initi-
ated and maintained at doses lower than the adult pop-
ulation.All of the SGAs appear to cause weight gain in
the adolescent population, which is the biggest draw-
back to their routine use; this appears to occur most
often with olanzapine and clozapine.Informed consent,
addressing the rationale for treatment and potential
risks and benefits of therapy, should be obtained from
the parents/guardians prior to treatment with any
antipsychotic medication and assent should be obtained
from the children.Standardized clinician rating,such as
the Positive and Negative Syndrome Scales (PANSSs)
derived from the Children’s Psychiatric Rating Scale,is
sensitive to antipsychotic improvements in children and
adolescents,and can be helpful in assessing the effects of
antipsychotic therapy.
Treatment of psychosis in the elderly
Schizophrenic symptoms in late life (>65 years) are gen-
erally a result of a chronic illness carrying over from
younger life; however, few patients may develop psy-
chotic symptoms de novo.
48 Data from the Epidemio-
logical Catchment Area Study
49 showed 6-month preva-
lence rates of schizophrenia in the elderly to be 0.2% to
0.9%.Other illnesses displaying psychotic symptoms are
extremely high in this population:0.1% to 1.6% for psy-
chotic depression and 16.8% to 23% for organic psy-
chosis.
49 Additionally, approximately one third of
patients with Alzheimer’s disease (AD),Parkinson’s dis-
ease (PD),and vascular dementia experience psychotic
symptoms and the majority of data for antipsychotic use
come from treating these disease states.
50-53
For institutionalized patients,antipsychotics are the most
widely prescribed psychotropic drugs.
54 Because of the
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125widespread and unnecessary use of these agents in the
US for this population in the past,Congress passed reg-
ulations governing use in 1987 with the Omnibus Budget
Reconciliation Act of 1987 (OBRA-87) and the Nursing
Home Reform Amendments administered by the
Health Care Financing Administration (HCFA).These
regulations developed specific standards for allowable
dosages and indications for psychotropic drugs in regu-
lar and as required (PRN) use.
55
Antipsychotics can be safe and effective for the treat-
ment of psychosis if used at lower doses than commonly
used in younger adults. Older adults are particularly
vulnerable to the side effects of conventional antipsy-
chotics.PD symptoms reportedly occur in over 50% of
all elderly patients receiving these agents and the cumu-
lative annual incidence of TD in middle-aged and
elderly patients is over 25%.
56The likelihood of revers-
ing this potentially debilitating condition diminishes
with age.Other adverse effects of these agents that are
often intolerable in the older population include ortho-
static hypotension and anticholinergic effects.Orthosta-
sis is estimated to occur in 5% to 30% of geriatric
patients and is a major contributing factor to the occur-
rence of falls.
57 The elderly are also more prone to the
consequences of falls, such as bone fractures, injuries,
and dependency.Low-potency antipsychotics and cloza-
pine are more likely to cause significant drops in ortho-
static blood pressure. Anticholinergic effects in the
elderly may cause side effects,such as constipation,dry
mouth, urinary retention, and cognitive impairment.
The elderly are especially sensitive to these effects and
the use of laxatives or stool softeners is already partic-
ularly high in nursing homes. Cognitive impairments
may lead to decreased independence,and a more rapid
decline in cognitive functioning may occur in the elderly
treated with antipsychotics than in the younger adult
population.
Clozapine has been used successfully in the elderly pop-
ulation at lower doses than adult patients.Mean dosages
range from 50 to 300 mg/day with a much slower rate of
titration.This may be a good choice for treating psychotic
elderly patients with preexisting PD,because of its lower
affinity for D2 receptors in the striatum. Clinically, how-
ever, it is a poorly tolerated antipsychotic in geriatric
patients and should be used with caution. The risk for
agranulocytosis appears to be about 4% in the elderly
population with older women being at highest risk.
58The
risk for seizure activity is increased in the elderly
59 and
sedation is one of the major reasons for discontinuation.
60
Clozapine therapy should be initiated at 12.5 to 25 mg/day
given in two divided doses, titrating by increments of 
12.5 mg over 5 to 7 days.Controlled studies examining the
efficacy of clozapine in the elderly specifically for patients
with schizophrenia are rare. Howanitz and colleagues
61
studied clozapine (maximum 300 mg/day) compared with
chlorpromazine (maximum 600 mg/day) in a 12-week,
double-blind fashion in patients with chronic schizophre-
nia. Patients on clozapine tended to do better than the
chlorpromazine group,although this did not reach signif-
icance,probably due to the sample size.
62Tachycardia and
weight gain were problematic for clozapine-treated
patients, while those treated with chlorpromazine were
highly sedated. Clozapine should be used as a last resort
in geriatric patients with schizophrenia and at least one
trial of an SGA should be made first.
Risperidone has been shown to be effective in the
elderly with schizophrenia, schizoaffective disorder,
major depression with psychotic features,bipolar disor-
der, and delusional disorder.A dosage range of 0.5 to 3
mg/day is the optimal range for the treatment of psy-
chotic symptoms in the elderly.Initially,patients should
receive 0.25 to 0.5 mg taken once daily with titration in
increments not greater than 0.5 mg/24 hours. A few
recent, large, open-label studies with risperidone for
geriatric patients with schizophrenia have been pub-
lished. A 12-month, multicenter trial included 180
patients with a mean age of 72 years and found that
54% of patients had a 20% reduction in PANSS scores
at a mean dosage of 3.7 mg/day.
63 Likewise, Madhu-
soondanan et al
64 found significant symptom improve-
ments over 12 weeks in 103 elderly patients with schizo-
phrenia or schizoaffective disorder. In these and other
open studies,risperidone is well tolerated with the most
common side effects being orthostatic hypotension and
sedation.The rates of EPS are low if risperidone is used
at low doses. Most elderly patients in the studies had
decreased use of anticholinergic medications and
improvements in EPS from baseline.The risk of TD with
risperidone treatment is significantly less than conven-
tional antipsychotic treatment in the geriatric popula-
tion (4% versus 25%).
63,65
Very little data exist for the treatment of schizophrenia
in the elderly with olanzapine. Very few patients over
65 were included in premarketing trials and no con-
trolled trials are yet available for this population. An
open-label study of olanzapine 5 to 20 mg/day found
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toms in schizophrenic patients aged 60 to 85 years.Side
effects were minimal and generally well tolerated.
Another open trial giving olanzapine as an adjunct
(mean dosage 8.4 mg/day) to current therapy found sig-
nificant improvements in EPS; however, no significant
improvements were noted on the Brief Psychiatric Rat-
ing Scale (BPRS).
66 Most other data available for olan-
zapine in the elderly relate to its use in AD and PD.
While low-dose olanzapine appears well tolerated and
effective for AD patients at dosages of 5 to 10 mg/day,
67
patients with PD suffer from unacceptable aggravation
of parkinsonism even at low doses.
68-73 The starting
dosage of olanzapine should be 2.5 to 10 mg/day and
increased by 5 mg no more frequently than every 7 days
to a target range of 5 to 15 mg/day in patients with schiz-
ophrenia and lower dosages for those with AD.
There are several reports of the use of quetiapine in the
elderly for the treatment of psychosis with PD.
74-78 On
the basis of both its receptor-binding affinity and its low
liability for EPS clinically,it is a good first-line selection
for this disorder and may be a option for patients who
have been taking clozapine.
79,80 Dosages for psychosis
associated with PD are generally 12.5 to 300 mg/day.No
controlled studies are currently available for quetiap-
ine use in patients with the diagnosis of schizophrenia
only. Two open-label studies and one case series have
been reported consisting of patients with a psychotic
disorder associated with a mixture of diagnoses and
found significant improvements in psychotic symp-
toms.
81-83 Somnolence, dizziness, and postural hypoten-
sion were the most frequently occurring adverse effects,
but the majority of cases were considered mild to mod-
erate.Weight gain and EPS occur at low rates with que-
tiapine use. Dosing for geriatric patients with schizo-
phrenia is not well studied. Dosages used in reports
averaged 100 to 150 mg/day, but these dosages were
studied in a population with mixed diagnoses.
SGAs appear to be beneficial in the geriatric popula-
tion at much lower doses than are used in adults.
Because geriatric patients are often on many medica-
tions and suffer from numerous disease states,vigilance
is needed when prescribing the newer medications.
Clozapine and olanzapine are metabolized by the
cytochrome P-450 isoenzyme 1A2,which may be inhib-
ited by several medications,therefore leading to higher
blood levels. This may be compounded in geriatric
patients by their already compromised metabolism and
clearance of medications. Additionally, women may
potentially be more prone to side effects,since the blood
levels of both these medications are higher in women
than men.
84,85 This population is particularly prone to
falls and anticholinergic side effects, such as constipa-
tion,confusion,blurry vision,urinary retention,and dry
mouth. All of these antipsychotics block  -receptors
leading to some orthostasis. Patients should be advised
to stand or sit up slowly,especially upon medication ini-
tiation. Using lower doses and selecting the least anti-
cholinergic of the medications helps prevent these other
adverse effects.
Very little data comparing these medications with con-
ventional agents or among SGAs are available. Queti-
apine should be used as a first-line agent for psychosis
associated with PD.
Treatment of schizophrenia 
in patients with substance abuse
The prevalence of substance abuse among persons with
schizophrenia is significantly higher than in the general
population. Conservative estimates are that one third
to as many as one half of people with schizophrenia
abuse alcohol and illicit drugs.
86,87 Dually diagnosed
patients are more likely to be noncompliant with treat-
ment and medications particularly because of side
effects.These people also have a poorer response rate to
traditional antipsychotics and have higher rates of rehos-
pitalization.
88-91 For patients discharged on traditional
antipsychotics, substance abuse is one of the most sig-
nificant reasons for readmission.
92,93 EPS may occur more
frequently in patients who are substance abusing, and
the use of illicit drugs and alcohol is a risk factor for the
development of TD.
94,95
There is evidence that substance-abusing patients
respond differently to conventional antipsychotics than
non–substance-abusing patients. A few studies have
reported that substance-abusing patients receiving fixed
doses of haloperidol and perphenazine had a poorer
response and more readmissions than non–substance-
abusing patients.
89,91 This is very likely due to the fact
that the substance-abusers suffer increased rates of
parkinsonian side effects from conventional antipsy-
chotics and are less compliant. Substance-abusing
patients usually have more floridly psychotic symptoms
and higher relapse rates.
88,90,96-99 Despite the fact that sub-
stance-abusing patients do poorly with traditional
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have better premorbid functioning and less functional
impairment than non–substance-abusing schizophrenic
patients.
100-102 It is possible that, while this group is diffi-
cult to treat, they may paradoxically represent a sub-
group with a better potential for recovery and perhaps a
better opportunity for successful reintegration into com-
munity living.
SGAs may offer effective clinical treatment for schizo-
phrenic patients with comorbid substance abuse.These
medications are associated with better compliance rates
than traditional agents as well as lower rates of rehospi-
talization.
103-105Additionally,they have very little liability
for causing TD. Unlike what has been observed during
conventional antipsychotic treatment, it has been
reported that treatment with clozapine is associated with
similar response rates between patients with and with-
out a history of substance abuse.
100,106 There is a rapidly
growing body of literature indicating that clozapine
treatment may actually be associated with a reduction in
the use of illicit drugs and alcohol,but no double-blind,
controlled studies are available.
107-111 Furthermore,cloza-
pine has been given to cocaine addicts prior to an
intranasal dose of cocaine and was noted to significantly
diminish the effects of the cocaine as well as lessen the
paranoia and nervousness associated with its use.
112
There are no controlled data available for dually diag-
nosed schizophrenic patients treated with risperidone.
There is no reason to believe, however, that this agent
would not be a good selection in patients with schizo-
phrenia and a current or past history of substance abuse.
It possesses the favorable benefits of the SGAs particu-
larly the lower recidivism and the risk for TD, which
may be of benefit in these dually diagnosed patients.
There are several case reports that risperidone is effec-
tive in substance abuse, such as amphetamine-induced
psychosis,inhalant abuse,cocaine craving,metampheta-
mine-associated obsessive-compulsive disorder, and
alcohol hallucinosis.
113-119 However,only one double-blind
trial exists examining risperidone use for cocaine depen-
dence,which found no reduction in cocaine use and low
tolerability even at low doses.
120 Therefore, risperidone
may offer benefits for the treatment of schizophrenic
symptoms, but there is little evidence that it will curb
drug use in this population.
The response to olanzapine in a population of schizo-
phrenic patients with and without a history of substance
abuse treated openly for 7 weeks was found to be sim-
ilar to that in a treatment-resistant population.
95 The
substance-abusing population had higher rates of TD at
baseline,which significantly improved during treatment.
Olanzapine has been compared with haloperidol in a
double-blind study for the treatment of cannabis-
induced psychotic disorder.These patients did not differ
in outcomes by drug group;however,those treated with
olanzapine had fewer EPS during treatment.
121Very lit-
tle additional data are available for dually diagnosed
patients treated with olanzapine.Likewise,few data are
available for comorbid substance abuse and the treat-
ment of schizophrenia with quetiapine.
Although the clinical reality of substance abuse among
patients with schizophrenia is widely known, the rela-
tionship of these diagnoses and optimal treatments is
neither well understood nor studied. Paradoxically,
dually diagnosed patients have a better potential for
recovery,but may have more symptomatology and side
effects.
122 From the data available, this population of
patients with schizophrenia will likely benefit more from
an SGA than a conventional treatment, and should be
expected to respond in the same way as those who are
not abusing. Clozapine is the only antipsychotic among
the SGAs that appears to provide additional benefits
to this group by actually reducing cravings for and use of
both illicit drugs and alcohol, but this needs to be stud-
ied in a controlled fashion.
Treatment-resistant schizophrenia
One fifth to one third of all cases of schizophrenia are
resistant to drug treatment.This finding has been con-
sistent over time.
123-125These patients are highly sympto-
matic and require extensive periods of hospital care.
126
There was a great deal of excitement following the
demonstration of clozapine's efficacy in inpatients with
treatment-resistant schizophrenia.
127 However, clozap-
ine treatment carries with it a significant morbidity from
serious side effects,the need for continual weekly blood
monitoring,and a high cost.Many clinicians and patients
hoped that other new antipsychotics would share cloza-
pine's effectiveness without its most serious side effects,
but no other antipsychotic in this group has clozapine's
efficacy.
Commonly, treatment resistance has been considered
to be roughly equivalent to chronic or frequent hospi-
talization.
128-133 This, by itself, is not an adequate defini-
tion.
134,135 Patients should also have current and persistent
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overall severity of illness in order for nonresponsive-
ness to apply,
136 as chronic hospitalization can occur
despite low levels of symptoms.
126 Many people with
schizophrenia who have been chronically hospitalized
may not be truly resistant to drug treatment.Inadequate
psychosocial programming, poor compliance with pre-
scribed drug therapy,or a history of committing violence
are all risk factors for chronic hospitalization.
134 There-
fore,an optimized medication and treatment trial should
be employed before a patient's illness is considered non-
responsive. In addition, the effects of drug noncompli-
ance and EPS can both mimic true treatment resis-
tance.
137,138 At least a 1- to 2-year course of persistent
symptoms should also be considered as one of the crite-
ria for treatment resistance in schizophrenia,because of
the waxing and waning course of this illness.
The most widely accepted current criteria for treatment
resistance in schizophrenia were first used by Kane et al.
127
These criteria,modified for clinical use,are as follows:
• Persistent positive psychotic symptoms (item score ≥ 4) on
at least two of four positive symptom items on the
BPRS:hallucinatory behavior,suspiciousness,unusual
thought content,or conceptual disorganization.
• Current presence of at least a moderately severe ill-
ness as rated by the total BPRS (score ≥ 45 on the 18-
item scale) and a score of ≥ 4 on the Clinical Global
Impression (CGI) scale.
• Persistence of illness: no period of good social and/or
occupational functioning within the last 5 years.
• Drug-refractory condition defined as at least two peri-
ods of treatment in the preceding 5 years with appro-
priate doses of conventional or SGAs, each without
clinically significant symptom relief.
The rates for two retrospective drug trial failures have
been found to be similar to the rates for three when
screening for treatment resistance;this fact is now widely
accepted.
138 People not responsive to two adequate
antipsychotic trials (one retrospective and one prospec-
tive) have less than a 7% chance of responding to
another trial.
139 The Food and Drug Administration
(FDA) guidelines for clozapine,as reflected in the prod-
uct labeling for clozapine,
140 also states that people
should fail to respond to two separate trials of antipsy-
chotics,before being treated with clozapine.
It is generally recognized that a 4- to 6-week period
(rather than strictly a 6-week one) is adequate for a
treatment trial of an antipsychotic.
141 Dosages of >400
mg/day of chlorpromazine have been shown to be ade-
quate to block 80% to 90% of dopamine receptors
(thought to be the target of this drug action).
142 Higher
doses produce no direct therapeutic benefit, even in
patients not responsive to therapy, and do not have
greater efficacy in acute treatment than lower doses.
143-145
Therefore, two 4- to 6-week trials of 400 to 600 mg/day
chlorpromazine or a chlorpromazine equivalent are now
accepted as a standard for an adequate trial.
138,146
Until the arrival of standardized criteria for defining
treatment resistance, research into the neurobiological
nature of the problem had been scant.
147 Recently,how-
ever, with the use of more objective criteria, some con-
sistent findings have been seen. There is a relative
paucity of data in this area and more research needs to
be done.People with treatment-resistant schizophrenia
appear to have increased cortical atrophy on magnetic
resonance imaging (MRI) compared with those with
responsive illness.
148,149 This was particularly true if they
had predominant negative symptoms.
150 Lack of
response to early treatment is also predictive of nonre-
sponse.
148 The most intriguing finding about predicting
which new drugs may be effective in treatment-resistant
schizophrenia has been the fact that these people appear
to have lower catecholamine levels in the cerebrospinal
fluid (CSF).
151 Clozapine response has been associated
with low ratios of CSF homovanillic acid to 5-hydroxy-
indoleacetic acid.
152 These findings suggest that drugs
with low dopamine antagonism and high serotonergic
antagonism may be particularly useful in treatment-
resistant schizophrenia.Also, cognitive disorganization
has recently been reported to be higher in patients with
treatment-resistance than in those who are partial or
full responders.
153
Historically,drug therapy for treatment-resistant schizo-
phrenia centered on the use of either different dose
strategies of conventional antipsychotics or adjunct
agents,such as lithium,β -blocking drugs,anticonvulsants,
and benzodiazepines.Since the arrival of clozapine,atten-
tion in the field has shifted to a greater focus on the use
of new antipsychotics for treatment resistance in schizo-
phrenia. This interest occurred because of the demon-
stration of the superior efficacy of clozapine and the fact
that new antipsychotics have been shown to have either
significantly fewer side effects or improved efficacy com-
pared with a conventional antipsychotic in order to be
marketed in the USA.Conventional antipsychotic med-
ications have worked poorly in this population and in
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fewer than 5% responded after having their drug therapy
changed from one conventional antipsychotic to
another.
127,154 SGAs should be the first consideration after
the failure of conventional drug therapy.These drugs are
also effective as first-line therapy (with the exception of
clozapine,because of its serious side effects).
Clozapine remains the only drug with proven efficacy in
rigorously defined treatment-resistant schizophrenia and
approximately 30% to 50% of treatment-refractory
patients will respond to this medication.
155 However,
fewer than 8% of new antipsychotic prescriptions are
written for this medication in the USA.This phenome-
non of relative underusage of clozapine probably relates
to the costs and complexities of clozapine therapy.These
arise from the need for long-term hematologic monitor-
ing for agranulocytosis and persistent serious side effects
present with clozapine, such as weight gain, sialorrhea,
and sedation.The optimal dose strategy for clozapine is a
slow dose escalation. Patients should be evaluated for
response at dosage plateaus of 200 to 400 mg/day and
500 to 600 mg/day.Only patients with few side effects to
clozapine should be titrated to dosages higher than 600
mg/day. Patients should not be titrated to a higher dose
of clozapine if myoclonus is present, as this side effect
may precede the development of seizures.
156
Risperidone has been found to be more effective than
conventional antipsychotics for positive and affective
symptoms in patients with acute schizophrenia.
36 For
patients with treatment resistance, the most rigorously
defined double-blind trial found a 24% response rate
to risperidone,compared with 11% for haloperidol after
4 weeks.
157 A few other double-blind studies have com-
pared risperidone with clozapine and found similar
response rates between drugs, but concerns about the
inclusion criteria have been raised.
158,159 Another open
study by Flynn et al
160 reported response rates to cloza-
pine of 44%, compared with 28% to risperidone. It
appears from the data available that risperidone is not
associated with a clozapine-like response, but is associ-
ated with response rates of approximately 25%, higher
than those of conventional antipsychotic treatments.
A few studies have reported favorable response rates
to olanzapine in patients with treatment-resistant schiz-
ophrenia of 36% to 47%.
161-163 However, there is some
controversy regarding these findings. These studies
included patients who were considered treatment-resis-
tant and those who were intolerant to clozapine.A study
by Conley et al
164 in well-characterized,treatment-resis-
tant patients with schizophrenia found only a 7%
response rate to olanzapine in this population and 41%
of these treatment failures went on to respond to cloza-
pine.
165 Likewise, an open trial of olanzapine in treat-
ment-refractory patients reported no significant
improvements in patients treated for at least 6 weeks
on 10 to 20 mg/day.
166 Therefore, olanzapine does not
have a pattern of response similar to clozapine in a well-
characterized sample,but may offer a slightly better rate
of response than traditional antipsychotic therapy.
Very little data on quetiapine use in treatment-resistant
schizophrenia are available.A few brief reports suggest
it may be beneficial to chronic or partial conventional
responders
167-169; however, no controlled trials for treat-
ment resistance have been published.
If patients remain refractory to treatment after trials of
SGAs,alternative therapies should be considered.Most
of the data for adjunctive treatment are, however, lim-
ited and come from case reports and open trials.
Adjunct lithium therapy has been seen to be beneficial
in some patients with treatment-resistant schizophre-
nia; however, these patients were often not defined by
the rigorous criteria of later studies.
123,129,170The published
trials of adjunct lithium that are positive were conducted
with small numbers of patients,and the criteria for defin-
ing treatment resistance were often not clear, or were
overinclusive.
171 More recent reports have found no ben-
efits with adjunct lithium therapy and fluphenazine
decanoate.
172 A recent report of 5 male patients with
schizophrenia treated with olanzapine showed signifi-
cant improvements with the addition of lithium.
173
Lithium should be used with caution in combination
with conventional antipsychotics or clozapine because of
the recognized dangers of delirium,encephalopathy,and
neurotoxicity that have been reported with these com-
binations.
138,174,175
Carbamazepine and valproic acid have been observed to
be effective in bipolar disorder
176,177 and are often consid-
ered as an adjunctive therapy in patients with schizo-
phrenia.However,these trials included relatively few sub-
jects. Positive effects seen with carbamazepine and
valproate have been modest and usually involved non-
specific improvement in areas such as behavior and social
adjustment.Carbamazepine should be used with caution
because it is a potent enzyme inducer and can also reduce
the blood level of haloperidol by as much as 50%.
178 Car-
bamazepine should not be used in combination with
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130clozapine.There are few data for newer anticonvulsants;
however,a few positive results were seen with lamotrigine
adjunctive treatment with clozapine.
179
Electroconvulsive therapy (ECT) for treatment-refrac-
tory schizophrenia has had favorable response in short-
term trials when added to antipsychotic medications.
However, in spite of more than five decades of wide-
spread clinical use, the administration of ECT lacks a
strong research base.A recent literature review
180 reports
that about 20% patients will have improvement with
this combination.Several recent case reports have noted
improvements and controlled trials are currently under-
way.
181-185 The combined treatment with clozapine
appears to be well tolerated and associated with few
adverse effects. However, the issues of persistence of
effect and long-term maintenance of these patients have
not yet been adequately addressed.
Combined antipsychotic therapy has recently drawn some
attention, as many patients (approximately 15%) cur-
rently are treated in this way.
186While this use is growing,
little research is available to support this treatment
approach.
187The most consistent data thus far come from
a few case reports suggesting added improvements to
clozapine treatment by the addition of risperidone.
188-192
Two cases of olanzapine addition to clozapine have
reported favorable results.
193 There is report of the com-
bined use of risperidone and olanzapine with success.
194
Other reports include the addition of pimozide,sulpiride,
and loxapine to treatment-resistant patients treated with
clozapine.
195-198 The addition of a antipsychotic with D2-
blocking abilities may enhance clozapine treatment in
partial responders,but large-scale studies are needed.
Other adjunctive therapies reported are associated with
very little data or have not been clearly found to be use-
ful for treating symptoms of schizophrenia.There have
been some reports of benzodiazepines,
130,199 but no clear
benefits in symptoms other than associated anxiety have
been found.
128,131,200,201There are historical studies suggest-
ing that  -blockers may be useful in refractory schizo-
phrenia.
135 However, there are no available controlled
studies using current diagnostic criteria. There is very
limited evidence that long-term therapy with β -blockers
is beneficial.
202
A defined approach to patients with treatment-resistant
schizophrenia is critical.As the antipsychotics being intro-
duced today may have different mechanisms of action
from conventional antipsychotics and from each other,
clinicians will need to explore the possibility of response
with each of these new agents in turn with their patients
who suffer from persistently refractory symptoms. To
date, clozapine is the only mediation with demonstrated
efficacy in treatment resistance.The differential efficacy of
new drugs in treatment-resistant schizophrenia will only
be clear when well-designed, double-blind studies using
rigorous entry criteria are completed.❑
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Tratamiento del paciente especial con
esquizofrenia
Las poblaciones de pacientes especiales con esqui-
zofrenia han recibido poca atención. Estas pobla-
ciones incluyen a los adolescentes, los viejos, los
abusadores de sustancias y a los pacientes que se
consideran resistentes al tratamiento. El interés en
estas poblaciones ha sido de una rapidez creciente
especialmente en relación con el tratamiento con
antipsicóticos de segunda generación. Este artículo
describe el tratamiento de las poblaciones de
pacientes especiales y resume la investigación que
se ha realizado en este campo.
Traitement des populations particulières de
patients atteints de schizophrénie
Les populations particulières de patients présen-
tant une schizophrénie ont jusqu'ici reçu peu
d’attention. Ces populations comprennent les
adolescents, les patients âgés, les toxicomanes et
les patients qui sont considérés comme résistants
au traitement. L’intérêt que l’on porte à ces
populations est en pleine expansion, en particu-
lier pour ce qui est de leur traitement par les
antipsychotiques de deuxième génération. Cet
article décrit le traitement de populations parti-
culières de patients et fait le point sur la
recherche dans ce domaine.Clinical research
132
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